Search research articles
Contact Us
Filters
Showing results (101-110 of 118) with videos related to
Page
of 12
Sort By:
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
December 14, 2007
Preclinical efficacy of the c-Met inhibitor CE-355621 in a U87 MG mouse xenograft model evaluated by 18F-FDG small-animal PET
Jeffrey R Tseng, Keon Wook Kang, Mangal Dandekar, et al.
International Journal of Radiation Oncology, Biology, Physics
|
January 1, 1992
Pharmacologic/pharmacokinetic evaluation of emesis induced by analogs of RSU 1069 and its control by antiemetic agents
J S Sebolt-Leopold, P W Vincent, K A Beningo, et al.
Cancer Chemotherapy and Pharmacology
|
February 9, 2000
Anticancer efficacy of the irreversible EGFr tyrosine kinase inhibitor PD 0169414 against human tumor xenografts
P W Vincent, A J Bridges, D J Dykes, et al.
Plastic and Reconstructive Surgery
|
February 2, 2023
Intramuscular Nanofat Injection Promotes Inflammation-Induced Gastrocnemius Regeneration in a Syngeneic Rat Sciatic Nerve Injury Model
Benjamin K Schilling, Jocelyn S Baker, Chiaki Komatsu, et al.
Journal of Medicinal Chemistry
|
February 7, 2001
Tyrosine kinase inhibitors. 17. Irreversible inhibitors of the epidermal growth factor receptor: 4-(phenylamino)quinazoline- and 4-(phenylamino)pyrido[3,2-d]pyrimidine-6-acrylamides bearing additional solubilizing functions
J B Smaill, G W Rewcastle, J A Loo, et al.
Journal of Medicinal Chemistry
|
March 26, 1998
Tyrosine kinase inhibitors. 14. Structure-activity relationships for methylamino-substituted derivatives of 4-[(3-bromophenyl)amino]-6-(methylamino)-pyrido[3,4-d]pyrimidine (PD 158780), a potent and specific inhibitor of the tyrosine kinase activity of receptors for the EGF family of growth factors
G W Rewcastle, D K Murray, W L Elliott, et al.
HGG Advances
|
March 14, 2026
Impaired retinoic acid receptor-γ signalling underlies a heritable form of urothelial keratinising squamous metaplasia
Kaya Fukushima, Nicole Avery, Jade Desjardins, et al.
Journal of Medicinal Chemistry
|
July 21, 2001
Tyrosine kinase inhibitors. 18. 6-Substituted 4-anilinoquinazolines and 4-anilinopyrido[3,4-d]pyrimidines as soluble, irreversible inhibitors of the epidermal growth factor receptor
J B Smaill, H D Showalter, H Zhou, et al.
ACS Medicinal Chemistry Letters
|
November 16, 2023
Optimization of mTOR Inhibitors Using Property-Based Drug Design and Free-Wilson Analysis for Improved In Vivo Efficacy
Sean T Murphy, Joy Atienza, Jason W Brown, et al.
Molecular Cancer Therapeutics
|
November 8, 2014
Antitumor activity of the MEK inhibitor TAK-733 against melanoma cell lines and patient-derived tumor explants
Lindsey N Micel, John J Tentler, Aik-Choon Tan, et al.
Page
of 12
Search research articles
Search
Showing results (101-110 of 118) with videos related to
Sort By:
Page
of 12
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
December 14, 2007
Preclinical efficacy of the c-Met inhibitor CE-355621 in a U87 MG mouse xenograft model evaluated by 18F-FDG small-animal PET
Jeffrey R Tseng, Keon Wook Kang, Mangal Dandekar, et al.
International Journal of Radiation Oncology, Biology, Physics
|
January 1, 1992
Pharmacologic/pharmacokinetic evaluation of emesis induced by analogs of RSU 1069 and its control by antiemetic agents
J S Sebolt-Leopold, P W Vincent, K A Beningo, et al.
Cancer Chemotherapy and Pharmacology
|
February 9, 2000
Anticancer efficacy of the irreversible EGFr tyrosine kinase inhibitor PD 0169414 against human tumor xenografts
P W Vincent, A J Bridges, D J Dykes, et al.
Plastic and Reconstructive Surgery
|
February 2, 2023
Intramuscular Nanofat Injection Promotes Inflammation-Induced Gastrocnemius Regeneration in a Syngeneic Rat Sciatic Nerve Injury Model
Benjamin K Schilling, Jocelyn S Baker, Chiaki Komatsu, et al.
Journal of Medicinal Chemistry
|
February 7, 2001
Tyrosine kinase inhibitors. 17. Irreversible inhibitors of the epidermal growth factor receptor: 4-(phenylamino)quinazoline- and 4-(phenylamino)pyrido[3,2-d]pyrimidine-6-acrylamides bearing additional solubilizing functions
J B Smaill, G W Rewcastle, J A Loo, et al.
Journal of Medicinal Chemistry
|
March 26, 1998
Tyrosine kinase inhibitors. 14. Structure-activity relationships for methylamino-substituted derivatives of 4-[(3-bromophenyl)amino]-6-(methylamino)-pyrido[3,4-d]pyrimidine (PD 158780), a potent and specific inhibitor of the tyrosine kinase activity of receptors for the EGF family of growth factors
G W Rewcastle, D K Murray, W L Elliott, et al.
HGG Advances
|
March 14, 2026
Impaired retinoic acid receptor-γ signalling underlies a heritable form of urothelial keratinising squamous metaplasia
Kaya Fukushima, Nicole Avery, Jade Desjardins, et al.
Journal of Medicinal Chemistry
|
July 21, 2001
Tyrosine kinase inhibitors. 18. 6-Substituted 4-anilinoquinazolines and 4-anilinopyrido[3,4-d]pyrimidines as soluble, irreversible inhibitors of the epidermal growth factor receptor
J B Smaill, H D Showalter, H Zhou, et al.
ACS Medicinal Chemistry Letters
|
November 16, 2023
Optimization of mTOR Inhibitors Using Property-Based Drug Design and Free-Wilson Analysis for Improved In Vivo Efficacy
Sean T Murphy, Joy Atienza, Jason W Brown, et al.
Molecular Cancer Therapeutics
|
November 8, 2014
Antitumor activity of the MEK inhibitor TAK-733 against melanoma cell lines and patient-derived tumor explants
Lindsey N Micel, John J Tentler, Aik-Choon Tan, et al.
Page
of 12